538P Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial

Pascale Tomasini; Julien Mazières; Claire Cropet; Xavier Troussard; David Malka; Isabelle Laure Ray-Coquard; Sophie Leboulleux; Aude Fléchon; Bertrand Arnulf; Mathilde Cancel; Ivan Bièche; S. Collot; S. Taïeb; Gabriel Garcia; A.M. Mandache; N. Colignon; Marie Gavrel; Marta Jimenez; Natalie Hoog-Labouret; Jean Yves Blay

doi:10.1016/j.annonc.2020.08.652

Article2023

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

Jean Yves Blay, Claire Cropet, Sandrine Mansard, Yohann Loriot, Christelle de la Fouchardière, Julien Haroche, Delphine Topart, David Tougeron, Benoît You, Antoîne Italiano, Valérie Le Brun-Ly, Jean-Marc Ferrero, Nicolas Penel, Michel Fabbro, Xavier Troussard, David Malka, Isabelle Ray‐Coquard, Sophie Leboulleux, Aude Fléchon, E. Maubec, J. Charles, Stéphane Dalle, S. Taïeb, Gabriel Garcia, A.M. Mandache, N. Colignon, Marie Gavrel, F. Nowak, N. Hoog Labouret, Céline Mahier - Aït Oukhatar, Carlos Gomez‐Roca

Article2020

538P Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial

Discussion(0)

Related publications

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> V600-Mutant Non-Melanoma Cancers

Data from Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i><sup>V600</sup>-Mutant Non-Melanoma Cancers

Data from Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i><sup>V600</sup>-Mutant Non-Melanoma Cancers

Supplementary Data from Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i><sup>V600</sup>-Mutant Non-Melanoma Cancers

538P Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial

Discussion(0)

Related publications

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> V600-Mutant Non-Melanoma Cancers

Data from Pan-Cancer Efficacy of Vemurafenib in &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600&lt;/sup&gt;-Mutant Non-Melanoma Cancers

Data from Pan-Cancer Efficacy of Vemurafenib in &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600&lt;/sup&gt;-Mutant Non-Melanoma Cancers

Supplementary Data from Pan-Cancer Efficacy of Vemurafenib in &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600&lt;/sup&gt;-Mutant Non-Melanoma Cancers

Data from Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i><sup>V600</sup>-Mutant Non-Melanoma Cancers

Data from Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i><sup>V600</sup>-Mutant Non-Melanoma Cancers

Supplementary Data from Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i><sup>V600</sup>-Mutant Non-Melanoma Cancers